FinancialApps, LLC v. Envestnet, Inc.

District Court, D. Delaware·Decided September 13, 2023·No. 1:19-cv-01337·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

FINANCIALAPPS, LLC, ) ) Plaintiff, ) ) v. ) Civil Action No. 19-1337-GBW-CJB ) ENVESTNET, INC. and YODLEE, INC., ) ) Defendants. )

MEMORANDUM ORDER Pending before the Court in this action is Defendants Envestnet, Inc. (“Envestnet”) and Yodlee, Inc.’s (“Yodlee,” and collectively with Envestnet, “Defendants”) motion to exclude the opinions and testimony of Plaintiff FinancialApps, LLC’s (“Plaintiff” or “FinApps”) damages expert, DeForest McDuff (“McDuff”). (D.I. 463) For the reasons set out below, the Court GRANTS-IN-PART and DENIES-IN-PART the Motion. I. BACKGROUND The Court will write here for the parties, and so it will forego a lengthy recitation of the facts. To the extent certain facts are relevant to resolution of the Motion, they will be set out in Section III. The Motion was filed on January 12, 2023. (D.I. 463) Briefing on the Motion was completed on April 27, 2023. (D.I. 561) The Court’s referral in the case from United States District Judge Gregory B. Williams includes authority to resolve the instant Motion. (D.I. 437) II. STANDARD OF REVIEW The Court has frequently set out the relevant standard of review for assessing a motion, like this one, filed pursuant to Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharms, Inc., 509 U.S. 579 (1993). One such instance came in Integra LifeScis. Corp. v. HyperBranch Med. Tech., Inc., Civil Action No. 15-819-LPS-CJB, 2018 WL 1785033, at *1-2 (D. Del. Apr. 4, 2018). The Court incorporates by reference those legal standards set out in Integra, and will follow them herein. To the extent that additional related legal principles regarding Rule 702 and Daubert are relevant, the Court will set those out in Section III.

III. DISCUSSION With their Motion, Defendants make three different broad sets of arguments as to why McDuff’s opinions should be excluded: (1) that his so-called “Harm to FinApps” analysis should be excluded; (2) that his so-called “Value to Defendants” analysis should be excluded; and (3) that his opinions on trade secret value should be excluded. The Court will address these arguments in turn. A. McDuff’s “Harm to FinApps” Analysis For his “Harm to FinApps” analysis, McDuff calculates such harm in two ways. First, for his low estimate, McDuff calculates the difference between FinApps’ costs to develop Risk Insight1 and its actual returns under the parties’ related Software License and Master Services

Agreement (“MSA”). (D.I. 465, ex. 1 (“McDuff Opening Rep.”) at ¶¶ 61-62) He opines that were it not for Defendants’ wrongful conduct, FinApps would have made at least as much as it spent on developing Risk Insight (the “Cost approach”). (Id. at ¶¶ 61-62, 64) Second, for his high estimate, McDuff calculates the difference between certain forward-looking revenue projections related to Risk Insight and FinApps’ actual returns under the MSA. (Id. at ¶¶ 43-44) He opines that were it not for Defendants’ wrongful conduct, FinApps’ actual returns under the

1 Risk Insight is a software product that FinApps developed and that Yodlee marketed and sold, until Defendants allegedly misappropriated FinApps’ related trade secrets in order to develop a different product. MSA would have met the projections and continued beyond the term of the MSA (the “Income + Market approach”). (Id. at ¶¶ 44, 50) Defendants assert that McDuff’s “Harm to FinApps” Analysis should be excluded for a number of reasons. The Court will address each such reason below.

1. Whether McDuff Sufficiently Ties Damages to the Alleged Misconduct

Defendants first argue that McDuff used an unreliable methodology in assessing how much financial harm Defendants’ alleged misconduct inflicted on FinApps. They say this is so because McDuff “does not show that the failure of Risk Insight to meet expectations was caused by the alleged misconduct.” (D.I. 464 at 3 (emphasis added))2 To what extent was McDuff required to attempt to affirmatively demonstrate that Defendants’ alleged misconduct caused the damages at issue? On the one hand, there are some cases (with egregious-sounding facts) where courts have excluded an expert’s damages analysis when the expert did not sufficiently explain how the misconduct in question caused or was linked to the damages sought. See MicroStrategy Inc. v. Bus. Objects, S.A., 429 F.3d 1344, 1355-56 (Fed. Cir. 2005) (affirming the exclusion of a damages expert’s report in part because “the excluded expert report did not link a single loss to a specific misconduct[,]” in a circumstance where it was clear that the expert “ignored significant factors that might have excluded the [alleged misconduct] as the reason for the losses”); AgroFresh Inc. v. Essentiv LLC, C.A. No. 16-662 (MN), 2019 WL 9514565, at *1 (D. Del. Oct. 7, 2019) (excluding a damages

2 In their opening brief, Defendants additionally argued that McDuff’s harm analysis was faulty because he assumed Defendants’ liability in assessing the damages owed. (D.I. 464 at 4, 7) But damages experts may properly assume the opposing party’s liability (when it is established independently), see Allscripts Healthcare, LLC v. Andor Health, LLC, Civil Action No. 21-704-MAK, 2022 WL 3021560, at *22 n.158 (D. Del. July 29, 2022), and in their reply brief, Defendants conceded as much, (D.I. 561 at 1). expert’s testimony where the expert “fails to connect the trade secret (or any other) issues in the case with his sums of costs[,]” and where the extent of the expert’s opinion was “a summation of costs from two general aspects of Plaintiff’s business” that were not connected at all to the trade secrets at issue). On the other hand, there are plenty of opinions that state that a damages expert

is entitled to presume causation, and may then simply go on to describe what damages were purportedly caused by the misconduct in question. See, e.g., Robroy Indus.-Tex., LLC v. Thomas & Betts Corp., Case No. 2:15-CV-512-WCB, Case No. 2-16-CV-198-WCB, 2017 WL 1319553, at *4-6 (E.D. Tex. Apr. 10, 2017) (citing cases) (Bryson, J., sitting by designation); Gaedeke Holdings VII, Ltd v. Baker, Case No. CIV-11-649-M, 2015 WL 11570978, at *3 (W.D. Okla. Nov. 30, 2015). The Court need not endeavor to reconcile these competing strands of caselaw. That is because the record indicates that McDuff did attempt to explain why Defendants’ misconduct in fact caused the damages in question. Defendants argue that this is not so, asserting that the “record is full of alternative

explanations for Risk Insight’s poor performance, and McDuff does not meaningfully explore any of them.” (D.I. 464 at 1) More specifically, Defendants argue that: • McDuff ignores the high rate of failure for startups and new ventures;

• McDuff ignores evidence of challenging market conditions;

• McDuff ignores evidence that FinApps’ platform (the “Platform”) is not advanced or unique; and

• McDuff ignores evidence of Risk Insight’s poor performance.

(Id. at 4-7) Yet McDuff did in fact address each of these alternative explanations highlighted by Defendants—explaining why he did not find them persuasive (and thus why, in the absence of any other explanation he could think of, Defendants’ misconduct had to have been the cause for Risk Insight’s failure). (See D.I. 465, ex. 2 at 208-209) In that regard: • McDuff confronted the literature that Defendants’ damages expert cited regarding the high rate of failure for startups and new ventures. He explained why this literature was “flawed and unreliable[,]” and why FinApps was not, in his view, properly considered a new technology venture.

Free access — add to your briefcase to read the full text and ask questions with AI

FinancialApps, LLC v. Envestnet, Inc., (D. Del. 2023).

FinancialApps, LLC v. Envestnet, Inc. (FinancialApps, LLC v. Envestnet, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
WWP, INC. v. Wounded Warriors Family Support, Inc.
628 F.3d 1032 (Eighth Circuit, 2011)
Microstrategy, Inc. v. Business Objects, s.a.
429 F.3d 1344 (Federal Circuit, 2005)
ZF Meritor LLC v. Eaton Corporation
696 F.3d 254 (Third Circuit, 2012)
In re: Avandia Marketing v.
924 F.3d 662 (Third Circuit, 2019)
Syngenta Crop Protection, LLC v. Willowood Azoxystrobin, LLC
267 F. Supp. 3d 649 (M.D. North Carolina, 2017)
Apotex, Inc. v. Cephalon, Inc.
321 F.R.D. 220 (E.D. Pennsylvania, 2017)